Mental health and brain alterations in children with multiple early risks
Summary
This study will investigate the impact of prenatal alcohol exposure on children's brain development and mental health. By understanding alterations in neurobiology, effective screening and treatment methods can be developed.
Participants will be asked to complete an MRI scan and cognitive assessments at the Alberta Children's Hospital. We are asking for a two-year time commitment. Participants will be compensated with a gift card.
Eligibility
Eligible ages: 7 to 21
Accepts healthy participants: Yes
Inclusion criteria:
1. Children and youth aged 7-21 years old
2. Children and youth with OR without prenatal alcohol exposure
3. Able to tolerate a 60-minute MRI scan, and 2-4 hour neuropsychological assessment
Exclusion criteria:
1. Children with braces, or other metal implants that are contraindicated for MRI
2. Children born under 34 weeks (born more than 6 weeks premature)
3. Children diagnosed with Autism Spectrum Disorder, psychosis, or genetic disorders
Participate
Fill out the following form if you want to participate in this research
UCalgary Notice of Collection
The University of Calgary (UCalgary) respects your privacy and is
committed to ensuring the privacy of all students, staff, and community members. Your personal information is being
collected under the authority of section 4(c) of the Protection of Privacy Act (POPA). It will be collected, used
and disclosed for the purposes outlined in UCalgary’s
Notice of
Collection, Use and Disclosure of Personal Information and managed in accordance with UCalgary’s
Privacy
Management Program.
Your personal information may be input into automated systems to generate content or make decisions,
recommendations, or predictions. If you have questions regarding this notice or UCalgary’s collection,
use, or disclosure of your personal information, please contact
accessandprivacy@ucalgary.ca.
Additional information
Contact information
Sara Xue at brainmri@ucalgary.ca
Principal investigator:
Catherine Lebel
Clinical trial:
No
REB-ID:
REB17-0663
External links